Xenon Pharmaceuticals (XENE) Competitors

Xenon Pharmaceuticals (NASDAQ:XENE) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Is XENE or BBIO more profitable?

Xenon Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -524.25%. BridgeBio Pharma's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-32.44%	-30.84%
BridgeBio Pharma	-524.25%	N/A	-94.43%

Which has higher valuation and earnings, XENE or BBIO?

Xenon Pharmaceuticals has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	322.08	-$234.33M	-$3.23	-9.75
BridgeBio Pharma	$221.90M	40.19	-$535.76M	-$3.53	-13.31

Which has more risk and volatility, XENE or BBIO?

Xenon Pharmaceuticals has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.

Do insiders and institutionals hold more shares of XENE or BBIO?

95.4% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 5.5% of Xenon Pharmaceuticals shares are held by company insiders. Comparatively, 18.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Do analysts rate XENE or BBIO?

Xenon Pharmaceuticals presently has a consensus price target of $54.82, suggesting a potential upside of 74.14%. BridgeBio Pharma has a consensus price target of $61.20, suggesting a potential upside of 30.30%. Given Xenon Pharmaceuticals' higher probable upside, equities research analysts clearly believe Xenon Pharmaceuticals is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	3.00
BridgeBio Pharma	0 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media prefer XENE or BBIO?

In the previous week, BridgeBio Pharma had 16 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 22 mentions for BridgeBio Pharma and 6 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.00 beat BridgeBio Pharma's score of 0.82 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	7 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Xenon Pharmaceuticals beats BridgeBio Pharma on 8 of the 15 factors compared between the two stocks.